- Home
- QNRX
as 03-24-2025 4:00pm EST
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | KFAR SABA |
| Market Cap: | 2.5M | IPO Year: | N/A |
| Target Price: | $4.00 | AVG Volume (30 days): | 8.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.27 - $1.57 | Next Earning Date: | 03-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Quoin Pharmaceuticals Ltd. News
QNRX Breaking Stock News: Dive into QNRX Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
7 days ago
QNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26
GlobeNewswire
12 days ago
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
GlobeNewswire
18 days ago
Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
Zacks Small Cap Research
19 days ago
QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease
GlobeNewswire
20 days ago
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
GlobeNewswire
25 days ago
Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study
GlobeNewswire
a month ago
Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome
GlobeNewswire
2 months ago
Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure
Compare QNRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QNRX Quoin Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.